The Association of Healthcare Professionals says the National Drug Regulatory Authority should also take responsibility for causing a shortage of life-saving drugs in government hospitals and forcing innocent patients to die prematurely.
The forum also points out that the company should take responsibility for the delay in performing its duties due to improper performance of duties related to the importation of drugs.
About 5,000 relevant files have been handed over by the importers to the National Drug Regulatory Authority for the importation of drugs, of which not a single file has been piled up without proper preparation for the importation of drugs. All of these files apply to the importation of new drugs. The reason for the shortage of drugs in the country is the delay in the registration of these files.
Meanwhile, the files pertaining to the drugs registered for import have been handed over to the regulatory authority for re-registration but no action has been taken to complete them. The number of such re-registered files is about eighteen thousand.
Thus, the number of files that should be provided as required for the importation of drugs but not provided is twenty three thousand. How to import the required drugs to the country is a serious question if the required number of files for each drug has not been released.
According to the Ministry of Health, the Chairman of the National Drug Regulatory Authority and other officials in charge of the relevant divisions are responsible for all this.
Officials at the agency point out that the chairman, who is an age-old agent, makes arbitrary decisions at his own discretion and excludes skilled and experienced seniors from the regulatory authority and draws in loyal friends who are loyal to him.
Professors of Pharmacology have been appointed as Chairmen of the Drug Regulatory Authorities in South Asia, and from the day the National Drug Regulatory Authority was established, it has been chaired by Professors with knowledge and understanding relevant to this field. However, the current chairman is a general practitioner who does not have the knowledge and experience in administration and scope. Now this institution has become a king of the Kusitas.
The Drug Regulatory Authority (DRA) is considered a national body for the development of local drug production, but says it does not actively support programs initiated by such institutions.
He pointed out that although the National Drug Regulatory Authority Act has legal provisions to prescribe a pricing mechanism for pharmaceutical equipment and limited products, the Authority's failure to set up such a committee is a serious shortcoming. The Prime Minister had pointed out at a recent meeting with key officials that the importation of drugs into the country has been severely hampered due to the weakness and inefficiency of the regulatory authority.
It has been decided at the discussion chaired by the Prime Minister that if there is a delay in approving the files related to the importation of drugs, such situations should be considered as an emergency and action should be taken to approve the importation of the files by a special committee.
Meanwhile, the National Drug Regulatory Authority (NDRA) has announced that if new pharmaceutical documentation is accepted from May 17, 2022, it will be limited to one item per week from one institution. The owners of these pharmaceutical companies are questioning how such restrictions on local pharmaceutical manufacturers can help the development of pharmaceutical products in the country.
No comments:
Post a Comment